CAR T-cell therapy is a remarkable new modality for treating cancer. Specially engineered T-cells have unlocked new potential in cancer treatment, especially for patients with lymphoma or leukemia. At Stanford, we’ve developed our own proprietary CAR T technology that is showing incredible responses. Stanford Cancer Institute Director Steven Artandi, MD, PhD, speaks to some of the incredible advances in CAR T-cell therapy our team at Stanford has made.

Learn more about Director Steven Artandi, MD, PhD:
[ Ссылка ]
Follow: [ Ссылка ]

Learn more about the Stanford Cancer Institute: [ Ссылка ]

Follow the Stanford Cancer Institute
LinkedIn: [ Ссылка ]
Twitter: [ Ссылка ]
Instagram: [ Ссылка ]

свернуть